- Company
- ‘No-show vaccines’ as the way out of COVID-19
- by An, Kyung-Jin May 28, 2021 06:08am
- J, who works as a medical representative in A Pharmaceuticals, has been struggling with his smartphone for 3 hours. J had finished his lunch early to try and reserve the no-show vaccines. However, both the Naver and Kakao applications on his phone were not working. Even after the server was restored, both maps were full of
- Company
- NA bill to guarantee labor succession following M&A
- by May 28, 2021 06:08am
- A bill that guarantees the succession of labor relations in changing businesses such as mergers or business transfers is being promoted. With the introduction of such a bill soon expected, eyes are on whether and how the pharmaceutical industry will also be affected by the bill. In particular, the bill is expected to pull the brakes on the u
- Company
- Olumiant's indication for atopic dermatitis has expanded
- by May 28, 2021 06:08am
- Lilly's Olumiant (Baricitinib) is the first Korean JAK inhibitor to acquire atopic dermatitis. Lilly Korea announced on the 26th that Olumiant received approval from the MFDS to expand its indications to treat secondary or severe atopic dermatitis in adult patients subject to systemic therapy on the 24th. Olumiant has acquired two indicati
- Company
- Daewoong & Dong-A succeeded in overcoming patent of Otezla
- by Kim, Jin-Gu May 27, 2021 05:56am
- Daewoong & Dong-A ST succeeded in avoiding one of two patents of Otezla (Apremilast), a psoriasis treatment drug worth &8361;2.46 trillion in global sales. While Amgen, the original company, has yet to officially release Otezla in Korea, the two companies are on the verge of releasing generics early. According to the pharmaceutical ind
- Company
- AD drug ‘Dupixent’ records ￦13.5 bil. in Q1 with reimb.
- by An, Kyung-Jin May 27, 2021 05:56am
- Sanofi Genzyme’s biologic medication ‘Dupixent (dupilumab),’ which was finally approved for reimbursement after a long wait, is creating a sensation in the market. After receiving approval for its reimbursement in severe atopic dermatitis last year, sales of Dupixent rose steeply to exceed 10 billion won in the first quarter this year. With t
- Company
- Sales of EGFR anticancer drug Tagrisso have been put on hold
- by An, Kyung-Jin May 27, 2021 05:56am
- The market for EGFR lung cancer drugs has been put on hold. Sales of Tagrisso, a third-generation drug, have declined since its benefit. As new products emerge one after another, the market is expected to change within this year. According to IQVIA, a pharmaceutical research institute, the size of Korea's market for EGFR tyrosine kinase inhib
- Company
- MSD's HIV market entry to be discussed at June's DREC meetin
- by Eo, Yun-Ho May 26, 2021 06:06am
- MSD is pushing to enter the HIV treatment market in Korea. Industry sources have reported that MSD Korea’s once-daily fixed-dose HIV combination tablet ‘Delstrigo (doravirine/lamivudine/tenofovir)’ will be reviewed by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC) meeting held in Ju
- Company
- Sales of obesity drugs have been on the decline
- by An, Kyung-Jin May 26, 2021 06:05am
- The rise in the obesity treatment market, which had high sales, has slowed. The effects of the new products of Saxenda and Qsymia has decreased. According to IQVIA, a pharmaceutical research institute, the domestic obesity treatment drug market was &8361;32 billion in the first quarter, down 2.4% from &8361;32.8 billion a year earlier. A
- Company
- Tylenol sales up 43% for use ‘after COVID-19 vaccination'
- by Kim, Jin-Gu May 26, 2021 06:05am
- Sales of Tylenol surged 43% YoY, compared to the same quarter of the previous year in the OTC pain medication market. This is in stark contrast to the double-digit decline in sales of other pain medications. Analysts believe that this increase in sales was influenced by the government’s guidance to ‘use Tylenol when experiencing side eff
- Company
- Sales of Prevenar 13 in the first quarter fell 46%
- by Chon, Seung-Hyun May 26, 2021 06:05am
- Sales of Pfizer's pneumococcal vaccine Prevenar 13 fell by half year-on-year in the first quarter. Although sales soared after the spread of Covid-19 last year, it seems to have returned to the previous year's level this year. According to IQVIA, a pharmaceutical research institute on the 24th, Prevenar 13's sales in the first quarter fell 46
